收费全文 | 14448篇 |
免费 | 981篇 |
国内免费 | 246篇 |
耳鼻咽喉 | 374篇 |
儿科学 | 191篇 |
妇产科学 | 264篇 |
基础医学 | 2286篇 |
口腔科学 | 234篇 |
临床医学 | 1058篇 |
内科学 | 3233篇 |
皮肤病学 | 351篇 |
神经病学 | 969篇 |
特种医学 | 1164篇 |
外科学 | 2024篇 |
综合类 | 43篇 |
现状与发展 | 1篇 |
一般理论 | 2篇 |
预防医学 | 344篇 |
眼科学 | 505篇 |
药学 | 1190篇 |
中国医学 | 195篇 |
肿瘤学 | 1247篇 |
2023年 | 78篇 |
2022年 | 83篇 |
2021年 | 557篇 |
2020年 | 305篇 |
2019年 | 446篇 |
2018年 | 508篇 |
2017年 | 397篇 |
2016年 | 623篇 |
2015年 | 815篇 |
2014年 | 983篇 |
2013年 | 1086篇 |
2012年 | 1565篇 |
2011年 | 1401篇 |
2010年 | 957篇 |
2009年 | 789篇 |
2008年 | 1011篇 |
2007年 | 901篇 |
2006年 | 777篇 |
2005年 | 643篇 |
2004年 | 514篇 |
2003年 | 422篇 |
2002年 | 394篇 |
2001年 | 59篇 |
2000年 | 43篇 |
1999年 | 36篇 |
1998年 | 34篇 |
1997年 | 24篇 |
1996年 | 27篇 |
1995年 | 15篇 |
1994年 | 20篇 |
1993年 | 23篇 |
1992年 | 13篇 |
1991年 | 13篇 |
1990年 | 16篇 |
1989年 | 14篇 |
1988年 | 14篇 |
1987年 | 11篇 |
1986年 | 7篇 |
1985年 | 7篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1982年 | 7篇 |
1981年 | 5篇 |
1980年 | 3篇 |
1979年 | 5篇 |
1978年 | 2篇 |
1977年 | 3篇 |
1973年 | 2篇 |
1972年 | 2篇 |
1969年 | 2篇 |
Background
Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.Objectives
To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.Methods
Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.Results
Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.Conclusions
These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study. 相似文献Methods: Fifty-five treatment-naïve neovascular AMD eyes (53 patients) were retrospectively included for analysis. All patients were treated with three loading injections of anti-VEGF agent, followed by further injections as required. The lesion size and vascular density of type 1 and 2 lesions before and after treatment for 12 months were analyzed using optical coherence tomography angiography (OCTA).
Results: The mean lesion size of the type 1 neovascularization group (42 eyes) showed no significant change from 2.12 ± 1.01 mm2 at baseline to 2.08 ± 0.91 mm2 at 12 months (P = .682). However, the mean lesion size of type 2 neovascularization significantly decreased from 1.23 ± 0.93 mm2 at baseline to 0.79 ± 0.61 mm2 at 12 months (P = .022). The proportion of eyes with lesion sizes that decreased by more than 40% from baseline was also significantly higher for the type 2 compared to the type 1 neovascularization group (46.2% versus 11.9%, P = .007). Vascular density showed no significant changes for both groups after treatment and showed no association with the change in lesion size. There was no significant difference between the groups in terms of visual acuity improvement.
Conclusion: OCTA analysis revealed different responses to anti-VEGF treatment depending on the location of neovascularization in neovascular AMD. Type 2 neovascularization was significantly regressed compared to type 1 neovascularization after anti-VEGF treatment. However, the changes in vascular density and visual outcome showed no significant differences between groups after 12 months of treatment. 相似文献